ADJUVANT BESTATIN (UBENIMEX) TREATMENT FOLLOWING FULL-DOSE LOCAL IRRADIATION FOR BLADDER-CARCINOMA

被引：6

作者：

BLOMGREN, H ^{[1
]}

ESPOSTI, PL ^{[1
]}

NASLUND, I ^{[1
]}

JOHANSEN, L ^{[1
]}

LEMMING, O ^{[1
]}

机构：

[1] LUNDBECK A-S,VALBY,DENMARK

来源：

ACTA ONCOLOGICA | 1990年 / 29卷 / 06期

关键词：

Bestatin; Bladder cancer; Radiotherapy;

D O I：

10.3109/02841869009093005

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

The clinical value of adjuvant bestatin (Ubenimex) immunotherapy has been examined in a group of patients with urinary bladder cancer. Patients with non-metastatic transitional cell carcinoma of the bladder, scheduled for full-dose local irradiation therapy (64 Gy), were randomly allocated to adjuvant oral bestatin treatment (30 mg daily for at least 1 year), starting at completion of irradiation, or no bestatin. The trial included 194 evaluable patients with a follow-up period of 1.5-9.5 years. The overall survival of the two groups of patients did not differ statistically significantly (97 patients in each). Subgrouping of the patient material gave no evidence that the clinical efficacy of bestatin is related to sex, tumor category or malignancy grade. ©1990 Informa UK Ltd All rights reserved: reproduction in whole or part not permitted.

引用

页码：809 / 812

页数：4

共 21 条

[1]

Aoyagi T, 1977, Jpn J Antibiot, V30 Suppl, P121

[2]

BLOMGREN H, 1987, CANCER IMMUNOL IMMUN, V25, P41

[3]

BLOMGREN H, 1984, BIOMED PHARMACOTHER, V38, P143

[4]

BLOMGREN H, 1986, BIOMED PHARMACOTHER, V40, P50

[5]

BLOMGREN H, 1983, CLIN IMMUNOL NEWSL, V4, P15

[6]

BRULEYROSSET M, 1979, IMMUNOLOGY, V38, P75

[7] RADIATION TREATMENT OF URINARY-BLADDER CARCINOMA [J].

EDSMYR, F ;

GIERTZ, G ;

ESPOSTI, PL ;

LITTBRAND, B .

UROLOGICAL RESEARCH, 1978, 6 (04) :229-232

[8]

ISCHIZUKA M, 1980, J ANTIBIOT, V33, P642

[9] BACILLUS CALMETTE-GUERIN IMMUNOTHERAPY FOR BLADDER-CANCER [J].

LAMM, DL .

JOURNAL OF UROLOGY, 1985, 134 (01) :40-47

[10]

Morales A, 1978, Natl Cancer Inst Monogr, P315

← 1 2 3 →